Pegylated liposomal doxorubicin plus bortezomib in relapsed or
refraktory multiple myeloma: efficacy and safety in patients
with renal function impairment.

J 2008

Pegylated liposomal doxorubicin plus bortezomib in relapsed or refraktory multiple myeloma: efficacy and safety in patients with renal function impairment.

BLADÉ, J., P. SONNEVELD, JF. SAN MIGUEL, HJ. SUTHERLAND, Roman HÁJEK et. al.

Basic information

Original name

Pegylated liposomal doxorubicin plus bortezomib in relapsed or refraktory multiple myeloma: efficacy and safety in patients with renal function impairment.

Name in Czech

Liposomální doxorubicin a bortezomib u relaxovaného refrakterního mnohočetného myelomu: účinnost a bezpečnost u pacientů s poškozenou funkcí ledvin

Authors

BLADÉ, J., P. SONNEVELD, JF. SAN MIGUEL, HJ. SUTHERLAND, Roman HÁJEK, A NAGLER, A SPENCER, T ROBAK, MT CIBEIRA, SH ZHUANG, JL HAROUSSEAU and RZ ORLOWSKI

Edition

Clinical lymphoma & myeloma, Dallas, United States, Cancer Information Group, 2008, 1557-9190

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30200 3.2 Clinical medicine

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 1.596

Organization unit

Faculty of Medicine

UT WoS

000261462300005

Keywords in English

doxorubicin;bortezomib

Abstract

ORIG CZ

V originále

A retrospective analysis was undertaken of patients (n = 193) with renal insufficiency (creatinine clearance [CrCl] < 60 mL/min) from a phase III trial comparing bortezomib +/- pegylated liposomal doxorubicin (PLD) in relapsed/refractory myeloma (n = 646). The response rate (49% vs. 42%) and median time to disease progression (331 days vs. 199 days) were comparable or slightly better for patients with renal insufficiency treated with PLD/bortezomib compared with patients treated with bortezomib alone. There was a steady, clinically meaningful improvement in renal function for patients with renal insufficiency in both treatment arms. However, patients with impaired renal function were at a slightly increased risk of a drug-related serious adverse event (28% vs. 19% for CrCl < 60 and > or = 60 mL/min, respectively).

In Czech

Byla sledována účinnost a bezpečnost Liposomální doxorubicin a bortezomib u relaxovaného refrakterního mnohočetného myelomu: u pacientů s poškozenou funkcí ledvin.

Citovat

BLADÉ, J., P. SONNEVELD, JF. SAN MIGUEL, HJ. SUTHERLAND, Roman HÁJEK, A NAGLER, A SPENCER, T ROBAK, MT CIBEIRA, SH ZHUANG, JL HAROUSSEAU and RZ ORLOWSKI. Pegylated liposomal doxorubicin plus bortezomib in relapsed or refraktory multiple myeloma: efficacy and safety in patients with renal function impairment. Clinical lymphoma & myeloma. Dallas, United States: Cancer Information Group, 2008, vol. 8, No 6, p. 352-355. ISSN 1557-9190.

@article{817650,
   author = {Bladé, J. and Sonneveld, P. and San Miguel, JF. and Sutherland, HJ. and Hájek, Roman and Nagler, A and Spencer, A and Robak, T and Cibeira, MT and Zhuang, SH and Harousseau, JL and Orlowski, RZ},
   article_location = {Dallas, United States},
   article_number = {6},
   keywords = {doxorubicin;bortezomib},
   language = {eng},
   issn = {1557-9190},
   journal = {Clinical lymphoma & myeloma},
   title = {Pegylated liposomal doxorubicin plus bortezomib in relapsed or refraktory multiple myeloma: efficacy and safety in patients with renal function impairment.},
   volume = {8},
   year = {2008}
}

TY  - JOUR
ID  - 817650
AU  - Bladé, J. - Sonneveld, P. - San Miguel, JF. - Sutherland, HJ. - Hájek, Roman - Nagler, A - Spencer, A - Robak, T - Cibeira, MT - Zhuang, SH - Harousseau, JL - Orlowski, RZ
PY  - 2008
TI  - Pegylated liposomal doxorubicin plus bortezomib in relapsed or refraktory multiple myeloma: efficacy and safety in patients with renal function impairment.
JF  - Clinical lymphoma & myeloma
VL  - 8
IS  - 6
SP  - 352-355
EP  - 352-355
PB  - Cancer Information Group
SN  - 15579190
KW  - doxorubicin;bortezomib
N2  - A retrospective analysis was undertaken of patients (n = 193) with renal insufficiency (creatinine clearance [CrCl] < 60 mL/min) from a phase III trial comparing bortezomib +/- pegylated liposomal doxorubicin (PLD) in relapsed/refractory myeloma (n = 646). The response rate (49% vs. 42%) and median time to disease progression (331 days vs. 199 days) were comparable or slightly better for patients with renal insufficiency treated with PLD/bortezomib compared with patients treated with bortezomib alone. There was a steady, clinically meaningful improvement in renal function for patients with renal insufficiency in both treatment arms. However, patients with impaired renal function were at a slightly increased risk of a drug-related serious adverse event (28% vs. 19% for CrCl < 60 and > or = 60 mL/min, respectively).
ER  -

BLADÉ, J., P. SONNEVELD, JF. SAN MIGUEL, HJ. SUTHERLAND, Roman HÁJEK, A NAGLER, A SPENCER, T ROBAK, MT CIBEIRA, SH ZHUANG, JL HAROUSSEAU and RZ ORLOWSKI. Pegylated liposomal doxorubicin plus bortezomib in relapsed or refraktory multiple myeloma: efficacy and safety in patients with renal function impairment. \textit{Clinical lymphoma \&{} myeloma}. Dallas, United States: Cancer Information Group, 2008, vol.~8, No~6, p.~352-355. ISSN~1557-9190.

Detailed Information on Publication Record